Microwave-assisted synthesis of optically active *N*-substituted 2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones and -thiazin-3(4*H*)-ones via Smiles rearrangement

Li-Juan Meng¹
Hua Zuo²
Zhu-Bo Li²
Gautam Dupati¹
Kiwan Jang¹
Gichuel Moon¹
Bao-Xiang Zhao³
Jun-Ying Miao³
Dong-Soo Shin¹

¹Departments of Chemistry and Physics, Changwon National University, Changwon, South Korea;
²College of Pharmaceutical Sciences, Southwest University, Chongqing, People's Republic of China;
³Institutes of Organic Chemistry and Developmental Biology, Shandong University, Jinan, People's Republic of China

Abstract: Optically active *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones and *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones with potential synthetic and pharmacological interest were prepared via Smiles rearrangement using microwave irradiation in one-pot from inexpensive (*S*)-2-chloropropionic acid.

Keywords: microwave-assisted synthesis, Smiles rearrangement, optically active oxazinones, chiral thiazinones

Introduction

The 1,4-benzoxazinone and 1,4-benzoxazine systems are intriguing because they are present in clinically significant pharmaceuticals and other biologically active molecules. Benzo[1,4]oxazin-3(4*H*)-ones are also known as 5-hydroxytryptamine-receptor antagonists,^{1–3} bladder-selective potassium channel openers, inhibitors of calcium channel, Na/H exchange inhibitors, antidepressants, dopamine D₂-receptor agonists, and inhibitors of phosphoinositide 3-kinase-γ.^{4–6} For example, SLV314 (Figure 1) is a promising novel antipsychotic, combining strong dopamine D₂-receptor antagonism with serotonin reuptake inhibitor effects in the same dose range, and was selected for clinical development.^{7–13} Some substituted [1,4]-oxazinones are also related to blocking the thromboxane A₂ receptor and activating the prostacyclin receptor.¹⁴ Moreover, certain kinds of benzo[1,4]oxazin-3(4*H*)-ones are of interest as photochromic compounds,^{15,16} and some possess herbicidal properties.¹⁷

Benzo[*b*][1,4]thiazin-3(4*H*)-ones exhibit different pharmacological activities: bacteriostatic,¹⁸ antimicrobial,¹⁹ antifungal,^{20,21} Na⁺/H⁺ exchange-system inhibitor,²² and calcium antagonist.^{23–25} For example, levosemotiadil (Figure 1), an *S*-enantiomer of semotiadil, is an antiarrhythmic drug that blocks sodium and calcium channels. Recently, it was reported that levosemotiadil also exhibited a potassium-blocking activity. Benzo[*b*][1,4]thiazin-3(4*H*)-ones are also useful as prophylactic drugs and/or therapeutic drugs in hyperlipemia, hyperglycemia, obesity, diseases attributable to sugar-tolerance insufficiency, hypertension, osteoporosis, cachexia, and complications of diabetes such as retinopathy, nephrosis, neuropathy, cataract, coronary artery disease, and arteriosclerosis.²⁶ Moreover, this class of compounds is used as herbicides.²⁷

[1,4]-Oxazinones and thiazinones have attracted considerable attention due to their pharmacological properties, as described above. The synthetic chiral benzo[1,4]-oxazinones and benzo[1,4]-thiazinones from substituted phenols and thio-phenols are greatly limited due to complicated methods or expensive materials. As a part of our

Correspondence: Dong-Soo Shin
Departments of Chemistry and Physics,
Changwon National University,
9, Sarim-dong, Changwon, GN,
641-773, South Korea

continuing efforts for the development of simpler and more convenient synthetic methods for interesting heterocyclic systems,²⁸ we herein describe a one-pot synthesis of diverse optically active *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones and *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones involving Smiles rearrangement.^{29–34} This work extends our previous report, in which we described the primary and optically inactive 2-chloroacetamides as starting materials.³⁵

Methods and materials

Melting points were determined on a MEL-TEMP® (Burlington, NJ, USA) capillary melting-point apparatus and are uncorrected. Optical rotations were measured with a Rudolph Autopol IV digital polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA). Nuclear magnetic resonance (¹H and ¹³C NMR spectra) was recorded in CDCl₃ (400 MHz for ¹H and 100 MHz for ¹³C) with trimethylsilane (TMS) as the internal reference on an Avance 400 FT spectrometer (Bruker, Billerica, MA, USA). Chemical shifts were reported in parts per million. Mass spectrometry (MS) was measured by electron impact (EI) method. Silica gel (D-6100, 70–230 mesh, ASTM; Merck, Darmstadt, Germany) was used for flash column chromatography. All reactions were monitored by thin layer chromatography (TLC) using 0.25 mm silica gel plates (Merck 60F-254) with or without an ultraviolet indicator. *N,N*-dimethylformamide (DMF) was distilled over anhydrous magnesium sulfate. All other reagents were commercially available and were used without further purification. All microwave-assisted reactions were carried out on a KMIC 1.5 kW creator from Korea Microwave Instrument (Suwon, South Korea). The microwave-assisted reaction time was the hold time at the final temperature.

General procedure for synthesis of (S)-*N*-substituted-2-chloropropanamide (3a–3d)

N,N'-Dicyclohexylcarbodiimide (DCC) was added (2.28 g, 11.05 mmol) to a solution of (S)-2-chloropropanoic acid (1.0 g, 9.21 mmol) at 0°C in dichloromethane. The resulting mixture was stirred for 30 minutes at 0°C, followed by the addition of amine (9.21 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was filtered, and the filtration cake was washed with dichloromethane carefully. The filtrate was concentrated to give the crude product. Pure product (yield 79%) was obtained by column chromatography using a mixture of hexane and ethyl acetate as eluent.

(S)-2-chloro-*N*-([tetrahydrofuran-2-yl]methyl)propanamide (3a)

A colorless oil; mp 73°C–74°C; [α]_D²⁰ –9.6 (*c* 1.0, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.50–1.58 (m, 1H), 1.71 (d, *J* = 7.2 Hz, 3H), 1.86–2.03 (m, 3H), 3.17–3.26 (m, 1H), 3.50–3.58 (m, 1H), 3.73–3.78 (m, 1H), 3.84–3.89 (m, 1H), 3.95–4.01 (m, 1H), 4.38 (q, *J* = 7.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 22.69, 22.80, 25.93, 28.59, 43.48, 55.94, 68.28, 169.74.

(S)-2-chloro-*N*-cyclohexylpropanamide (3b)

A white solid; mp 99°C–100°C; [α]_D²⁰ –12.3 (*c* 1.0, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.17–1.26 (m, 3H), 1.47–1.52 (d, *J* = 6.8 Hz, 3H), 1.69–1.75 (m, 3H), 1.89–1.99 (m, 2H), 2.13–2.33 (m, 2H), 4.40–4.45 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 22.92, 25.77, 26.34, 30.72, 30.74, 37.76, 46.04, 56.30, 169.46.

(S)-2-chloro-*N*-hexylpropanamide (3c)

A colorless oil; [α]_D²⁰ = –7.7 (*c* 1.0, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.88 (t, *J* = 5.2 Hz, 3H), 1.28 (s, 6H), 1.49 (t, *J* = 6.8 Hz, 2H), 1.69–1.71 (m, 3H), 3.22–3.27 (m, 2H), 4.36–4.41 (q, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 139.96, 22.50, 22.74, 26.46, 29.25, 31.40, 39.95, 55.99, 169.45.

(S)-2-chloro-*N*-([*R*]-1-phenylethyl)propanamide (3d)

A white solid; mp 100°C–101°C; [α]_D²⁰ +56.7 (*c* 1.0, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.53 (d, *J* = 7.2 Hz, 3H), 1.72 (d, *J* = 7.2 Hz, 3H), 4.42–4.47 (q, *J* = 7.2 Hz, 1H), 5.08–5.15 (m, 1H), 7.28–7.40 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 21.80, 22.67, 49.26, 56.02, 125.97, 127.54, 128.80, 142.61, 168.56.

General procedure for synthesis of (R)-4-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones (5a–5l)

The solution of chlorophenols (2.40 mmol), chloropropanamides (2.40 mmol), Cs₂CO₃ (2.40 g, 7.36 mmol) in dry DMF was placed into a microwave oven (KMIC 1.5 kW) at 130°C and irradiated for the period listed in Table 1. The solvent was evaporated under reduced pressure. The residue was poured into water and then extracted by ethyl acetate. The combined organic layers were dried over anhydrous MgSO₄. The solvent was removed under vacuum to obtain the crude product, which was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate.

Table 1 Synthesis of (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones with microwave irradiation

Entry	Amides	Phenols	Products	Time (min)	Yield (%) ^a
1				20	80
2	3a			30	77
3	3a			20	62
4	3a			25	68
5		4a		35	77
6	3b	4b		55	82
7	3b	4c		40	74
8	3b	4d		40	80
9		4a		30	83
10	3c	4b		40	78
11	3c	4c		35	65
12	3c	4d		30	71

Note: ^aYields refer to isolated pure compounds after column chromatography.

(2*R*)-7-chloro-2-methyl-4-([tetrahydrofuran-2-yl]methyl)-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-one (5a)

A colorless oil; $[\alpha]_D^{20} = -14.8$ (*c* 1.0, MeOH); infrared (KBr) ν/cm^{-1} : 3357, 3079, 2969, 2870, 1688, 1590, 1498, 1392, 1296, 1012, 863, 807, 719; ^1H NMR (400 MHz, CDCl_3) δ 1.52

(d, $J = 6.8$ Hz, 3H), 1.62–1.69 (m, 1H), 1.89–1.96 (m, 3H), 3.70–3.78 (m, 3H), 4.15–4.18 (m, 2H), 4.57–4.62 (q, $J = 6.8$ Hz, 1H), 6.94 (t, $J = 3.6, 2.0$ Hz, 2H), 7.20–7.28 (dd, $J = 17.2, 8.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.20, 25.57, 29.44, 46.74, 68.29, 73.65, 76.79, 116.70, 117.37, 122.60, 128.11,

128.62, 145.44, 166.46; MS (EI) m/z : 281 (M^+ , 25%), 211 (12), 197 (62), 182 (12), 154 (61), 85 (19), 71 (100).

(2R)-7-bromo-2-methyl-4-([tetrahydrofuran-2-yl]methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (5b)

A colorless oil; $[\alpha]_D^{20} = -13.8$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3357, 3083, 2969, 2870, 1684, 1586, 1494, 1388, 1296, 1073, 1012, 863, 807, 703; ^1H NMR (400 MHz, CDCl_3) δ 1.52 (d, $J = 6.8$ Hz, 3H), 1.61–1.70 (m, 1H), 1.87–1.98 (m, 3H), 3.71–3.78 (m, 3H), 4.15–4.18 (m, 2H), 4.57–4.63 (q, $J = 6.8$ Hz, 1H), 7.13–7.19 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.21, 25.57, 29.44, 46.69, 68.29, 73.66, 76.78, 115.92, 117.40, 120.22, 125.54, 129.15, 145.58, 166.49; MS (EI) m/z : 325 (M^+ , 20%), 255 (10), 241 (53), 226 (10), 200 (15), 85 (21), 71 (100).

(2R)-7-fluoro-2-methyl-4-([tetrahydrofuran-2-yl]methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (5c)

A colorless oil; $[\alpha]_D^{20} = -13.6$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3353, 3075, 2962, 2874, 1684, 1609, 1509, 1445, 1403, 1296, 1145, 1069, 1012, 852, 803; ^1H NMR (400 MHz, CDCl_3) δ 1.58 (d, $J = 6.8$ Hz, 3H), 1.63–1.71 (m, 1H), 1.89–1.97 (m, 3H), 3.69–3.75 (m, 3H), 4.16–4.20 (m, 2H), 4.66–4.71 (q, $J = 6.8$ Hz, 1H), 6.71–6.70 (m, 2H), 7.20–7.28 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.16, 25.53, 29.40, 46.97, 68.23, 73.67, 77.02, 104.72, 104.98 (d, $J_{\text{CF}} = 26$ Hz), 108.86, 108.96 (d, $J_{\text{CF}} = 10$ Hz), 116.49, 116.58 (d, $J_{\text{CF}} = 9$ Hz), 125.71, 125.74 (d, $J_{\text{CF}} = 3$ Hz), 145.02, 145.13 (d, $J_{\text{CF}} = 11$ Hz), 157.67, 157.72 (d, $J_{\text{CF}} = 5$ Hz), 116.31; MS (EI) m/z : 265 (M^+ , 35%), 195 (18), 181 (78), 166 (18), 152 (7), 138 (36), 85 (20), 71 (100).

(2R)-5-chloro-2-methyl-4-([tetrahydrofuran-2-yl]methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (5d)

A colorless oil; $[\alpha]_D^{20} = -15.4$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3372, 3079, 2958, 2870, 1692, 1574, 1460, 1373, 1267, 1077, 916, 783, 727; ^1H NMR (400 MHz, CDCl_3) δ 1.51–1.55 (m, 4H), 1.83–1.91 (m, 3H), 3.63–3.69 (m, 2H), 3.96–4.01 (m, 1H), 4.29–4.40 (m, 1H), 4.43–4.63 (m, 2H), 6.99–7.01 (m, 2H), 7.08–7.10 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 15.58, 25.55, 28.81, 46.54, 67.77, 74.60, 75.46, 116.06, 123.74, 125.22, 125.53, 128.32, 150.41, 169.84; MS (EI) m/z : 281 (M^+ , 6%), 211 (33), 197 (98), 182 (35), 71 (100), 168 (14), 154 (48), 85 (46).

(R)-7-chloro-4-cyclohexyl-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (5e)

A colorless oil; $[\alpha]_D^{20} = -17.1$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3357, 3079, 2932, 2859, 1684, 1586, 1494, 1445,

1365, 1289, 1106, 1026, 966, 867, 803; ^1H NMR (400 MHz, CDCl_3) δ 1.27–1.41 (m, 3H), 1.51 (d, $J = 6.8$ Hz, 3H), 1.71–1.82 (m, 3H), 1.88 (t, $J = 6.4$ Hz, 2H), 2.28–2.33 (m, 2H), 4.15–4.22 (m, 1H), 4.46–4.51 (q, $J = 6.8$ Hz, 1H), 6.98–7.02 (m, 2H), 7.08–7.10 (d, $J = 8.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.01, 25.38, 26.35, 26.42, 29.22, 29.65, 56.94, 74.54, 116.92, 118.05, 122.40, 128.45, 128.64, 146.43, 167.71; MS (EI) m/z : 279 (M^+ , 32%), 197 (100), 182 (10), 168 (6), 154 (43).

(R)-7-bromo-4-cyclohexyl-2-methyl-2H-benzo[b][1,4]oxazin-(4H)-one (5f)

A colorless oil; $[\alpha]_D^{20} = -16.9$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3353, 3075, 2932, 2859, 1684, 1590, 1494, 1369, 1289, 1110, 1069, 1026, 962, 860, 803; ^1H NMR (400 MHz, CDCl_3) δ 1.23–1.40 (m, 3H), 1.51 (d, $J = 6.8$ Hz, 3H), 1.70–1.81 (m, 3H), 1.87 (t, $J = 6.0$ Hz, 2H), 2.28–2.32 (m, 2H), 4.14–4.22 (m, 1H), 4.45–4.50 (q, $J = 6.8$ Hz, 1H), 7.02 (d, $J = 8.4$ Hz, 1H), 7.08–7.10 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.02, 25.38, 26.35, 26.42, 29.20, 29.63, 58.91, 74.54, 115.64, 117.32, 120.87, 125.33, 129.14, 146.56, 167.72; MS (EI) m/z : 325 (M^+ , 35%), 243 (100), 226 (10), 200 (40), 55 (10).

(R)-7-fluoro-4-cyclohexyl-2-methyl-2H-benzo[b][1,4]oxazin-(4H)-one (5g)

A colorless oil; $[\alpha]_D^{20} = -17.2$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3433, 3075, 2932, 2863, 1680, 1498, 1369, 1289, 1216, 1149, 1110, 1026, 981, 867, 799; ^1H NMR (400 MHz, CDCl_3) δ 1.27–1.41 (m, 3H), 1.51 (d, $J = 6.8$ Hz, 3H), 1.71–1.82 (m, 3H), 1.88 (t, $J = 6.4$ Hz, 2H), 2.28–2.33 (m, 2H), 4.15–4.22 (m, 1H), 4.46–4.51 (q, $J = 6.8$ Hz, 1H), 6.98–7.02 (m, 2H), 7.08–7.10 (d, $J = 8.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 15.96, 25.38, 26.34, 26.41, 29.24, 29.70, 56.98, 74.61, 105.36, 105.61 (d, $J_{\text{CF}} = 25$ Hz), 108.75, 108.97 (d, $J_{\text{CF}} = 22$ Hz), 116.68, 116.77 (d, $J_{\text{CF}} = 9$ Hz), 126.24, 126.27 (d, $J_{\text{CF}} = 3$ Hz), 146.73, 146.84 (d, $J_{\text{CF}} = 11$ Hz), 157.42, 159.85 (d, $J_{\text{CF}} = 43$ Hz), 167.58; MS (EI) m/z : 263 (M^+ , 40%), 181 (100), 166 (14), 152 (8), 138 (57).

(R)-5-chloro-4-cyclohexyl-2-methyl-2H-benzo[b][1,4]oxazin-(4H)-one (5h)

A colorless oil; $[\alpha]_D^{20} = -21.6$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3353, 3083, 2969, 2928, 2859, 1684, 1464, 1570, 1407, 1365, 1224, 1087, 1023, 932, 886, 734; ^1H NMR (400 MHz, CDCl_3) δ 1.20–1.30 (m, 3H), 1.51 (d, $J = 6.8$ Hz, 3H), 1.65 (d, $J = 11.6$ Hz, 1H), 1.80–1.88 (m, 3H), 2.16 (d, $J = 12.4$ Hz, 1H), 2.38–2.63 (m, 2H), 3.71–3.78 (m, 1H),

4.23–4.28 (q, $J = 6.8$ Hz, 1H), 6.95–7.01 (m, 2H), 7.09–7.13 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 15.14, 25.34, 26.59, 26.76, 29.26, 30.34, 63.22, 75.83, 115.60, 124.14, 124.88, 125.66, 130.61, 150.68, 169.91; MS (EI) m/z : 279 (M^+ , 19%), 197 (100), 182 (11), 168 (6), 154 (63).

(R)-7-chloro-4-hexyl-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (5i)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -9.7$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3353, 3075, 2932, 2863, 1688, 1590, 1498, 1400, 1293, 1149, 1110, 1012, 954, 867, 807, 723; ^1H NMR (400 MHz, CDCl_3) δ 0.88 (t, $J = 7.2$ Hz, 3H), 1.31–1.39 (m, 6H), 1.54 (d, $J = 6.8$ Hz, 3H), 1.60–1.65 (m, 2H), 3.87 (t, $J = 8.0$ Hz, 2H), 4.60–4.65 (q, $J = 6.8$ Hz, 1H), 6.87–6.90 (m, 1H), 6.99–7.02 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.97, 16.39, 22.53, 26.45, 27.01, 31.44, 41.63, 73.63, 115.39, 117.84, 122.50, 127.61, 128.46, 145.19, 166.02; MS (EI) m/z : 281 (M^+ , 85%), 211 (10), 197 (100), 182 (61), 168 (12), 154 (68).

(R)-7-bromo-4-hexyl-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (5j)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -9.3$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3345, 3072, 2932, 2859, 1684, 1593, 1494, 1369, 1293, 1149, 1106, 1069, 1016, 951, 863, 803, 719; ^1H NMR (400 MHz, CDCl_3) δ 0.89 (t, $J = 6.8$ Hz, 3H), 1.31–1.38 (m, 6H), 1.54 (d, $J = 6.8$ Hz, 3H), 1.60–1.66 (m, 2H), 3.87 (t, $J = 7.6$ Hz, 2H), 4.61–4.66 (q, $J = 6.8$ Hz, 1H), 6.83 (t, $J = 4.8$ Hz, 1H), 7.14–7.17 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.99, 16.41, 22.54, 26.46, 27.01, 31.45, 41.61, 73.65, 115.81, 120.69, 125.46, 128.11, 131.25, 145.34, 166.06; MS (EI) m/z : 325 (M^+ , 94%), 282 (14), 200 (64), 241 (100), 226 (62), 212 (11).

(R)-7-fluoro-4-hexyl-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (5k)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -9.9$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3353, 3079, 2932, 2863, 1684, 1609, 1509, 1453, 1407, 1296, 1194, 1141, 1012, 852, 799, 727; ^1H NMR (400 MHz, CDCl_3) δ 0.87 (t, $J = 6.8$ Hz, 3H), 1.29–1.39 (m, 6H), 1.54 (d, $J = 6.8$ Hz, 3H), 1.60–1.66 (m, 2H), 3.87 (t, $J = 7.6$ Hz, 2H), 4.60–4.65 (q, $J = 6.8$ Hz, 1H), 6.73–6.77 (m, 2H), 6.88–6.91 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.02, 16.38, 22.57, 26.48, 27.04, 31.47, 41.71, 73.67, 105.25, 105.50 (d, $J_{\text{CF}} = 25$ Hz), 108.84, 109.07 (d, $J_{\text{CF}} = 23$ Hz), 115.12, 115.21 (d, $J_{\text{CF}} = 9$ Hz), 125.21, 125.24 (d, $J_{\text{CF}} = 3$ Hz), 145.45, 145.56 (d, $J_{\text{CF}} = 11$ Hz), 157.52, 159.45 (d, $J_{\text{CF}} = 193$ Hz), 165.84; MS (EI) m/z : 265 (M^+ , 92%), 194 (13), 181 (100), 166 (81), 152 (17), 138 (83).

(R)-5-chloro-4-hexyl-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (5l)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -10.4$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3376, 3075, 2928, 2863, 1692, 1574, 1464, 1376, 1270, 1194, 1114, 1069, 940, 879, 776, 727; ^1H NMR (400 MHz, CDCl_3) δ 0.82 (t, $J = 6.8$ Hz, 3H), 1.23–1.38 (m, 6H), 1.51–1.59 (m, 5H), 4.10–4.17 (m, 1H), 4.23–4.30 (m, 1H), 4.35–4.40 (q, $J = 6.8$ Hz, 1H), 6.95–7.00 (m, 2H), 6.91–7.07 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.95, 15.38, 22.48, 26.06, 27.61, 31.27, 44.43, 74.56, 115.90, 123.46, 125.00, 125.64, 127.85, 150.00, 168.90; MS (EI) m/z : 281 (M^+ , 42%), 246 (20), 197 (100), 182 (44), 168 (8), 154 (70).

General procedure for synthesis of (R)-4-substituted-2-methyl-2H-benzo[b][1,4]thiazin-3(4H)-ones (7a–7j)

A solution of chlorobenzenethiol (2.23 mmol), (*S*)-*N*-furfuryl-2-chloropropanamide (0.427 g, 2.23 mmol), Cs_2CO_3 (2.18 g, 6.69 mmol) in dry DMF was placed into a microwave oven (KMIC 1.5 kW) at 130°C and irradiated for the period listed in Table 2. The solvent was evaporated under reduced pressure. The residue was poured into water and was then extracted by ethyl acetate. The combined organic layers were dried over anhydrous MgSO_4 . The solvent was removed under vacuum to obtain the crude product, which was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate.

(2R)-7-chloro-2-methyl-4-((tetrahydrofuran-2-yl)methyl)-2H-benzo[b][1,4]thiazin-3(4H)-one (7a)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -11.3$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3323, 3087, 2973, 2870, 1670, 1582, 1472, 1400, 1361, 1255, 1016, 867, 814, 730; ^1H NMR (400 MHz, CDCl_3) δ 1.50 (d, $J = 6.8$ Hz, 3H), 1.57–1.60 (m, 1H), 1.86–1.96 (m, 3H), 3.45–3.55 (m, 1H), 3.65–3.70 (q, $J = 6.8$ Hz, 1H), 3.86–3.95 (m, 2H), 4.30–4.37 (m, 2H), 7.20–7.22 (m, 1H), 7.32–7.34 (m, 1H), 7.50 (d, $J = 8.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.28, 29.46, 37.79, 51.07, 68.23, 77.30, 120.39, 125.50, 127.23, 127.56, 128.59, 138.89, 167.56; MS (EI) m/z : 297 (M^+ , 17%), 227 (13), 213 (100), 198 (20), 170 (23), 85 (24), 71 (86).

(2R)-8-chloro-2-methyl-4-((tetrahydrofuran-2-yl)methyl)-2H-benzo[b][1,4]thiazin-3(4H)-one (7b)

A colorless oil; $[\alpha]_{\text{D}}^{20} = -10.6$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3327, 3079, 2962, 2870, 1673, 1570, 1445, 1373, 1247, 1069, 973, 776, 711; ^1H NMR (400 MHz, CDCl_3)

Table 2 Synthesis of (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones with microwave irradiation

Entry	Amide	Benzenethiol	Products	Time (h)	Yield (%) ^a
1				18	92
2	3a			18	90
3	3a			25	82
4		6a		30	85
5	3b	6b		25	72
6	3b	6c		30	80
7		6a		18	85
8	3c	6b		18	72
9	3c	6c		20	80
10		6d		18	72

Note: ^aYields refer to isolated pure compounds after column chromatography.

δ 1.46 (d, J = 7.2 Hz, 3H), 1.68–1.75 (m, 1H), 1.84–1.86 (m, 3H), 3.24–3.35 (m, 2H), 3.84–3.95 (m, 2H), 4.08–4.16 (m, 2H), 7.14–7.17 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.30, 25.46, 26.49, 26.58, 29.89, 30.56, 39.71, 61.67, 117.76, 124.60, 126.56, 126.74, 132.95, 141.06, 168.89; MS (EI) m/z : 297 (M⁺, 19%), 227 (15), 213 (100), 198 (18), 170 (23), 85 (22), 71 (87).

(2*R*)-6-chloro-2-methyl-4-([tetrahydrofuran-2-yl]methyl)-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7c)

A colorless oil; $[\alpha]_D^{20}$ = –11.8 (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3083, 2973, 2870, 1670, 1574, 1468, 1411, 1347, 1247, 1103, 1073, 1019, 973, 871, 810, 723; ¹H NMR (400 MHz, CDCl₃) δ 1.48 (d, J = 6.8 Hz, 3H), 1.57–1.65 (m, 1H), 1.87–2.00 (m, 3H), 3.41–3.47 (q, J = 6.8 Hz, 1H),

Figure 1 Compounds containing 2*H*-benzo[*b*][1,4]-oxazin-3(4*H*)-one and 2*H*-benzo[*b*][1,4]-thiazine-3(4*H*)-one moieties.

3.61–3.67 (m, 1H), 3.88–3.97 (m, 2H), 4.18–4.35 (m, 2H), 6.97–7.01 (m, 1H), 7.23–7.26 (m, 1H), 7.60 (dd, $J = 1.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.22, 25.62, 29.45, 37.72, 51.18, 68.16, 77.14, 119.52, 122.12, 123.45, 128.80, 132.74, 141.2, 167.62; MS (EI) m/z : 297 (M^+ , 16%), 227 (12), 213 (100), 198 (20), 170 (21), 85 (24), 71 (84).

(*R*)-7-chloro-4-cyclohexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7d)

A colorless oil; $[\alpha]_D^{20} = -15.8$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3323, 3068, 2932, 2859, 2251, 1875, 1670, 1574, 1464, 1331, 1263, 1106, 1042, 901, 814, 734; ^1H NMR (400 MHz, CDCl_3) δ 1.22–1.39 (m, 3H), 1.42 (d, $J = 7.2$ Hz, 3H), 1.68–1.88 (m, 5H), 2.22–2.29 (m, 2H), 3.14–3.36 (q, $J = 7.2$ Hz, 1H), 4.10–4.18 (m, 1H), 7.16–7.21 (m, 2H), 7.37 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.50, 25.47, 26.48, 26.54, 29.99, 30.52, 39.94, 61.07, 120.44, 126.79, 127.64, 128.44, 128.71, 138.42, 168.96; MS (EI) m/z : 295 (M^+ , 28%), 213 (100), 198 (20), 184 (7), 170 (28), 154 (22).

(*R*)-8-chloro-4-cyclohexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7e)

A colorless oil; $[\alpha]_D^{20} = -13.5$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3331, 3072, 2932, 2859, 2662, 2251, 1673, 1570, 1449, 1347, 1247, 1190, 1050, 997, 901, 780, 727; ^1H NMR (400 MHz, CDCl_3) δ 1.21–1.42 (m, 3H), 1.46 (d, $J = 7.2$ Hz, 3H), 1.68–1.75 (m, 2H), 1.84–1.86 (m, 3H), 2.24–2.33 (m, 2H), 3.29–3.35 (q, $J = 7.2$ Hz, 1H), 4.08–4.16 (m, 1H), 7.14–7.17 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.30, 25.46, 26.49, 26.58, 29.89, 30.56, 39.71, 61.67, 117.76, 124.60, 126.56, 126.74, 132.95, 141.06, 168.89; MS (EI) m/z : 295 (M^+ , 40%), 213 (100), 198 (36), 184 (8), 170 (33), 154 (20).

(*R*)-6-chloro-4-cyclohexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7f)

A colorless oil; $[\alpha]_D^{20} = -16.0$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3334, 3072, 2932, 2859, 2662, 1666, 1574, 1456,

1331, 1232, 1099, 1046, 993, 867, 807, 756; ^1H NMR (400 MHz, CDCl_3) δ 1.27–1.42 (m, 6H), 1.68–1.76 (m, 2H), 1.81–1.89 (m, 3H), 2.27–2.33 (m, 2H), 3.27–3.33 (q, $J = 6.8$ Hz, 1H), 4.05–4.14 (m, 1H), 6.99–7.01 (dd, $J = 8.0$, 2.0 Hz, 1H), 7.20 (d, $J = 2.0$ Hz, 1H), 7.28 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.46, 25.43, 26.47, 26.53, 29.83, 30.37, 39.87, 61.43, 119.46, 123.56, 124.12, 129.65, 132.29, 140.88, 169.00; MS (EI) m/z : 295 (M^+ , 38%), 213 (100), 198 (21), 184 (9), 170 (30), 154 (22).

(*R*)-7-chloro-4-hexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7g)

A colorless oil; $[\alpha]_D^{20} = -7.7$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3334, 3068, 2932, 2863, 1673, 1578, 1472, 1403, 1365, 1312, 1255, 871, 810, 730; ^1H NMR (400 MHz, CDCl_3) δ 87 (t, $J = 6.8$ Hz, 3H), 1.28–1.38 (m, 6H), 1.45 (d, $J = 7.2$ Hz, 3H), 1.58–1.66 (m, 2H), 3.45–3.50 (q, $J = 7.2$ Hz, 1H), 3.92–4.01 (m, 2H), 7.02 (d, $J = 8.8$ Hz, 1H), 7.20–7.23 (dd, $J = 8.8$, 2.4 Hz, 1H), 7.35 (d, $J = 2.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.00, 15.04, 22.55, 26.35, 27.41, 31.44, 27.84, 45.23, 118.45, 124.83, 127.16, 128.35, 128.67, 137.58, 167.17; MS (EI) m/z : 297 (M^+ , 61%), 236 (25), 226 (25), 213 (100), 198 (45), 170 (40), 154 (12).

(*R*)-8-chloro-4-hexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7h)

A colorless oil; $[\alpha]_D^{20} = -6.8$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3331, 3072, 2928, 2859, 1916, 1677, 1570, 1453, 1373, 1304, 1251, 1190, 1099, 1038, 985, 772, 730; ^1H NMR (400 MHz,

Figure 2 Synthesis of *N*-substituted-(*S*)-2-chloropropanamide (3) from (*S*)-2-chloropropionic acid (1) and alkyl amines (2).

Abbreviation: DCC, *N,N'*-Dicyclohexylcarbodiimide.

Figure 3 Synthesis of *N*-substituted-(*R*)-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones (5).

Note: 3 = *N*-substituted-(*S*)-chloro propanamides; 4 = 2-chlorophenols.

Abbreviations: DMF, Dimethylformamide; MW, Microwave.

CDCl₃) δ 0.87 (t, J = 6.8 Hz, 3H), 1.27–1.36 (m, 6H), 1.48 (d, J = 7.2 Hz, 3H), 1.50–1.64 (m, 2H), 3.43–3.49 (q, J = 7.2 Hz, 1H), 3.95–4.00 (m, 2H), 7.03–7.05 (dd, J = 8.8, 1.2 Hz, 1H), 7.12–7.19 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.99, 14.85, 22.54, 26.38, 27.49, 31.43, 37.56, 45.74, 115.81, 123.98, 124.20, 126.95, 132.91, 140.15, 167.06; MS (EI) m/z : 297 (M⁺, 58%), 236 (40), 213 (100), 198 (56), 170 (46), 154 (18).

(*R*)-6-chloro-4-hexyl-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7i)

A colorless oil; $[\alpha]_D^{20} = -7.9$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3338, 3072, 2928, 2863, 1677, 1578, 1468, 1414, 1263, 1106, 981, 860, 814, 756, 727; ¹H NMR (400 MHz, CDCl₃) δ 0.87 (t, J = 7.2 Hz, 3H), 1.32–1.37 (m, 6H), 1.43 (d, J = 7.2 Hz, 3H), 1.61–1.65 (m, 2H), 3.42–3.47 (q, J = 7.2 Hz, 1H), 3.89–4.02 (m, 2H), 6.99–7.01 (dd, J = 8.4, 2.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.99, 14.97, 22.54, 26.33, 27.39, 31.40, 37.75, 45.27, 117.59, 121.38, 123.21, 129.58, 132.75, 139.97, 167.26; MS (EI) m/z : 297 (M⁺, 67%), 236 (25), 226 (21), 213 (100), 198 (44), 170 (40), 154 (12).

(*R*)-7-chloro-2-methyl-4-([*R*]-1-phenylethyl)-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (7j)

A colorless oil; $[\alpha]_D^{20} = -104.0$ (c 1.0, MeOH); IR (KBr) ν/cm^{-1} : 3323, 3065, 3034, 2985, 2938, 2247, 1673, 1582, 1472, 1403, 1376, 1335, 1243, 1099, 913, 871, 814, 746, 703; ¹H NMR (400 MHz, CDCl₃) δ 1.57 (d, J = 6.8 Hz, 3H), 1.66

(d, J = 6.8 Hz, 3H), 3.49–3.54 (q, J = 6.8 Hz, 1H), 6.37–6.42 (q, J = 6.8 Hz, 1H), 6.74 (d, J = 8.8 Hz, 1H), 6.96–6.99 (dd, J = 8.8, 2.4 Hz, 1H), 7.29–7.32 (m, 3H), 7.36–7.40 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.44, 16.61, 38.95, 52.76, 120.84, 125.93, 126.55, 127.08, 127.70, 128.24, 128.80, 128.89, 136.38, 141.16, 168.84; MS (EI) m/z : 317 (M⁺, 22%), 246 (5), 213 (100), 198 (10), 170 (17), 154 (12), 105 (84), 77 (15).

Results and discussion

Our synthesis started with preparation of optically active *N*-substituted-(*S*)-2-chloropropanamides (3). The optically active (*S*)-2-chloropropionic acid (1)³⁶ was successfully coupled with various amines (2), with DCC affording the corresponding amides (3) (Figure 2).

The reaction of *N*-substituted-(*S*)-2-chloropropanamide (3) with 2-chlorophenols (4) gave the corresponding (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones (5a–5l) via Smiles rearrangement in one pot. The reaction proceeded smoothly at 130°C under microwave irradiation in DMF solvent (Figure 3).

The results and reaction conditions for the synthesis of various novel (*R*)-2-methyl-benzo[*b*][1,4]oxazin-3(4*H*)-ones are given in Table 1. The successful one-pot synthesis of (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones encouraged us to explore the same approach to prepare (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones. Similarly, this one-pot reaction was carried out by mixing

Figure 4 Synthesis of *N*-substituted-(*R*)-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones (7).

Note: 3 = *N*-substituted-(*S*)-chloro propanamides; 6 = 2-chlorothiophenols.

Abbreviations: DMF, Dimethylformamide; MW, Microwave.

1 equiv of amide (3), 1 equiv of 2-chlorobenzenethiols (6) and 2.5 equiv of Cs_2CO_3 in dry DMF and then heating under microwave irradiation. The reaction temperature was maintained at 130°C for 30 minutes to obtain the corresponding (*R*)-*N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones (**7a–7j**) in 65%–90% yield (Table 2 and Figure 4).

The optical activities of final products indicate that *O*- or *S*-alkylation takes place via $\text{S}_\text{N}2$ process.³⁷ The gas chromatography–MS spectra of all the corresponding products clearly indicated the formation of the corresponding product, and IR, ^1H NMR and ^{13}C NMR spectra further confirmed the structures of various *N*-substituted-2-methyl-2*H*-benzo[*b*](1,4)-oxazin-3(4*H*)ones and *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones.

Conclusion

Novel optically active *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-ones and *N*-substituted-2-methyl-2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-ones with potential synthetic and pharmacological interest were synthesized via Smiles rearrangement by microwave irradiation in one pot. Further studies including biological activity testing and expansion of more derivatives are currently in progress in our laboratory.

Acknowledgments

This work was supported by grants from the Korea Ministry of Environment (KME, 412-111-008), the National Research Foundation of Korea (NRF-2010-0029634), and the Ministry of Knowledge Economy (MKE, R0000495).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Zhao SH, Berger J, Clark RD, et al. 3,4-Dihydro-2*H*-benzo[1,4]oxazine derivatives as 5-HT₆ receptor antagonists. *Bioorg Med Chem Lett*. 2007;17(12):3504–3507.
2. Dougherty KJ, Bannatyne BA, Jankowska E, Krutk P, Maxwell DJ. Membrane receptors involved in modulation of responses of spinal dorsal horn interneurons evoked by feline group II muscle afferents. *J Neurosci*. 2005;25(3):584–593.
3. Kawakita T, Kuroita T, Yasumoto M, et al. Synthesis and Pharmacology of 3,4-Dihydro-3-oxo-1,4-benzoxazine-8-carboxamide Derivatives, a New Class of Potent Serotonin-3 (5-HT₃) Receptor Antagonists. *Chem Pharm Bull*. 1992;40(3):624–630.
4. Jones JH, Anderson PS, Baldwin JJ, et al. Synthesis of 4-substituted 2*H*-naphth[1,2-*b*]-1,4-oxazines, a new class of dopamine agonists. *J Med Chem*. 1984;27(12):1607–1613.
5. Pieter S, Hein KACC, Hiskias GK, et al. Synthesis, Structure–Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1*H*-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D₂ Receptor Antagonism with Potent Serotonin Reuptake Inhibition. *J Med Chem*. 2005;48(22):6855–6869.
6. Lanni TB Jr, Greene KL, Kolz CN, et al. Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3 Kinase-gamma. *Bioorg. Med Chem Lett*. 2007;17(3):756–760.
7. Katsura Y, Nishino S, Takasugi H. Studies on Antiulcer Drugs. I. Synthesis and Antiulcer Activities of Imidazo[1,2-*a*] Pyridinyl-2-Oxobenzoxazolidines-3-Oxo-2*H*-1,4-Benzoxazines and Related Compounds. *Chem Pharm Bull*. 1991;39(11):2937–2943.
8. Kajino N, Shibouta Y, Nishikawa K, Meguro K. Synthesis and biological activities of new 2-substituted 1,4-benzoxazine derivatives. *Chem Pharm Bull*. 1991;39(11):2896–2905.
9. Fringuelli R, Pietrella D, Schiaffella F, et al. Synthesis and biological evaluation of 1-azabicyclo[3.2.1]octanes: new dopamine transporter inhibitors. *Bioorg Med Chem*. 2002;10(6):1681–1686.
10. Nair MG, Salter OC, Kisliuk RL, Gaumont Y. Folate analogs. 22. Synthesis and biological evaluation of two analogs of dihydrofolic acid possessing a 7,8-dihydro-8-oxapterin ring system. *J Med Chem*. 1983;26(8):1164–1168.
11. Wahidulla S, Bhattacharjee JJ. Benzoxazinoids from *Acanthus illicifolius*. *J Indian Inst Sci*. 2001;81:485–490.
12. Frechette R, Weidner-Wells M, inventors. Ortho Pharmaceutical Corporation, assignee. Benzoxazine antimicrobial agents. United States patent US5854242, December 29, 1998.
13. Buckman BO, Mohan R, Koovakkat S. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors. *Bioorg Med Chem Lett*. 1998;8(16):2235–2240.
14. Ohno M, Tanaka Y, Miyamoto M, et al. Development of 3,4-dihydro-2*H*-benzo[1,4]oxazine derivatives as dual thromboxane A₂ receptor antagonists and prostacyclin receptor agonists. *Bioorg Med Chem*. 2006;14(6):2005–2021.
15. Christie RM, Agyako CK, Mitchel K. An investigation of the electronic spectral properties of the merocyanines derived from photochromic spiroindolinonaphth[2,1-*b*][1,4]oxazines. *Dyes Pigments*. 1995;29(3):241–250.
16. Sun XD, Fan MG, Meng XJ, Knobbe ET. Acidichromic effects in spiro(1,3,3-trimethylindolo-2,3'-naphth[1,2-*b*]-1,4-oxazine) a photochromic compound I. Absorption characteristics. *J Photochem Photobiol. A*. 1997;102(2–3):213–216.
17. Huang MZ, Huang KL, Ren YG, et al. Synthesis and Herbicidal Activity of 2-(7-Fluoro-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl) isoindoline-1,3-diones. *J Agric Food Chem*. 2005;53(20):7908–7914.
18. Guarda VLM, Perrissin M, Thomasson F, et al. Synthesis of 4-octyl-2*H*-1,4-benzo-thiazin-3-ones. *Eur J Med Chem*. 2003;38(7–8):769–773.
19. Guarda VLM, Perrissin M, Thomasson F, et al. Synthesis and microbiological activity of some 4-butyl-2*H*-benzo[1,4]thiazin-3-one derivatives. *Il Farmaco*. 2001;56(9):689–693.
20. Pitzurra L, Fringuelli R, Perito S, et al. A New Azole Derivative of 1,4-Benzothiazine Increases the Antifungal Mechanisms of Natural Effector Cell. *Antimicrob Agents Chemother*. 1999;43(9):2170–2175.
21. Fringuelli R, Schiaffella F, Bistoni F, Pitzurra L, Vecchiarelli A. Azole derivatives of 1,4-benzothiazine as antifungal agents. *Bioorg Med Chem*. 1998;6(1):103–108.
22. Takeshi Y, Ikuro W, inventors. Kanebo Limited, assignee. Benzo[1,4]thiazine derivatives and drugs comprising the same. Japanese patent WO9813357, April 2, 1998.
23. Jun-ichi I, Tadashi I, Masayuki O, inventors. Santen Pharmaceutical Co, Ltd, assignee. Platelet anti-aggregative-and calcium antagonistic-1, 4-benzothiazin-3-one derivatives, compositions, and methods of use there for. US patent US4584300, April 22, 1986.
24. Henning R, Lerch U, Kaiser J, inventors. Hoechst Aktiengesellschaft, assignee. Benzothiazine derivatives. US patent US4595685, June 17, 1986.
25. Lerch U, Henning R, inventors. Hoechst Aktiengesellschaft, assignee. Benzothiazinone derivatives, process for their preparation, medicaments containing them and their use. US patent US4831028, May 16, 1989.
26. Yoshitake O, Yoichi K. Production of benzothiazine derivative. JP9012576, January 14, 1997.

27. Wuemachu T, Hasimoto S, inventors. Sumitomo Chemical, assignee. Process for preparing 1,4-benzothiazine derivatives. Korean patent KR 1019790001204, May 17, 1982.
28. Cho S-D, Park YD, Kim JJ, et al. A One-Pot Synthesis of Pyrido[2,3-*b*] [1,4]oxazin-2-ones. *J Org Chem*. 2003;68(20):7918–7920.
29. Ma C, Cho SD, Falck JR, Shin DS. Synthetic Studies on Isoquinoline Derivatives with Multidrug Resistance (MDR) Modulating Activity. *Heterocycles*. 2004;63(1):75–85.
30. Cho SD, Song SY, Park YD, et al. Novel synthesis of pyridazino[4,5-*b*] [1,4]oxazin-3,8-diones. *Tetrahedron Lett*. 2003;44(50): 8995–8998.
31. Cho SD, Park YD, Kim JJ, et al. An efficient synthesis of [1,4] pyridazinooxazine[3,4-*a*]tetrahydro isoquinolines. *Tetrahedron*. 2004;60(17):3763–3773.
32. Zuo H, Meng L, Ghathe M, et al. Microwave-assisted one-pot synthesis of benzo[*b*] [1,4]oxazin-3(4H)-ones via Smiles rearrangement. *Tetrahedron Lett*. 2008;49(23):3827–3830.
33. Zuo H, Li ZB, Ren FK, et al. Microwave-assisted one-pot synthesis of benzo[*b*] [1,4]thiazin-3(4H)-ones via Smiles rearrangement. *Tetrahedron*. 2008;64(41):9669–9674.
34. Zuo H, Kam KH, Kwan HJ, et al. Microwave-assisted synthesis of 2H-benzo[*b*] [1,4] oxazin-3(4H)-ones and 1H-Pyrido[2,3-*b*] [1,4]oxazin-2(3H)-ones via Smiles rearrangement. *Bull Korean Chem Soc*. 2008; 29(7):1379–1385.
35. Jongphil Kang J, Kam KH, Ghathe M, et al. An efficient synthesis of 2H-1,4-benzoxazin-3(4H)-ones via Smiles rearrangement. *ARKIVOC*. 2008:67–76.
36. Koppenhoefer B, Schurig V. (*s*)-2-chloroalkanoic acids of high enantiomeric purity from (*s*)-2-amino acids: (*s*)-2-chloropropanoic acid. *Organic Syn*. 1993;8:119–123.
37. Meng L, Zuo H, Vijaykumar BVD, et al. Microwave Synthesis of Chiral *N*-Benzyl-2-methyl-2H-benzo [b] [1, 4] oxazin/thiazin-3 (4H)-ones via Smiles Rearrangement and their Biological Evaluation. *Bull Korean Chem Soc*. 2013;34(2):585–589.

Research and Reports in Medicinal Chemistry

Publish your work in this journal

Research and Reports in Medicinal Chemistry is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of medicinal chemistry. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: <http://www.dovepress.com/research-and-reports-in-medicinal-chemistry-journal>

Dovepress

Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.